Cargando…

A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue

BACKGROUND: Schizophrenia is associated with high relapse rates, and medication nonadherence is a major factor contributing toward relapse. Since medication adherence and treatment awareness are linked, an alarming need was felt to evaluate the level of drug treatment awareness in patients who have...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripathi, Raakhi, Jalgaonkar, Sharmila, Gajbhiye, Snehalata, Khatri, Nishtha, Sayyed, Mohsin, Parkar, Shubhangi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120996/
https://www.ncbi.nlm.nih.gov/pubmed/35655976
http://dx.doi.org/10.1177/02537176211056358
_version_ 1784711059544735744
author Tripathi, Raakhi
Jalgaonkar, Sharmila
Gajbhiye, Snehalata
Khatri, Nishtha
Sayyed, Mohsin
Parkar, Shubhangi
author_facet Tripathi, Raakhi
Jalgaonkar, Sharmila
Gajbhiye, Snehalata
Khatri, Nishtha
Sayyed, Mohsin
Parkar, Shubhangi
author_sort Tripathi, Raakhi
collection PubMed
description BACKGROUND: Schizophrenia is associated with high relapse rates, and medication nonadherence is a major factor contributing toward relapse. Since medication adherence and treatment awareness are linked, an alarming need was felt to evaluate the level of drug treatment awareness in patients who have schizophrenia. Besides, patients who have schizophrenia are often dependent on their caregivers for medications. Hence, the current study was also designed to look into drug treatment awareness among caregivers. METHODS: This was a cross-sectional, questionnaire-based study. Patients diagnosed with schizophrenia as per The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition were included, provided they had good insight and had been prescribed medications at the study center for at least three months. Caregivers were included using the Pollak and Perlick criteria. The sociodemographic profile of the patients and caregivers was recorded, and further assessment for treatment awareness was done using the prevalidated Drug Treatment Awareness Questionnaire (DTAQ). RESULTS: A total of 166 patients and 157 caregivers were enrolled. Mean drug awareness scores among patients and caregivers did not show statistically significant differences (P= 0.22). Mean ± SD DTAQ awareness scores in patients and caregivers were 12.57 ± 1.81 and 12.84 ± 1.91, respectively. The majority of patients and caregivers (> 90%) possessed awareness in domains related to past medication records and in that of re-visit/re-contact instructions. Awareness was least commonly seen in relation to side effects of medications and details of the prescribed medications, where only about 50% of patients and caregivers possessed awareness. No clinically significant correlation was found between sociodemographic factors and drug treatment awareness scores. CONCLUSION: Drug treatment awareness in patients and caregivers was comparable and was not reliant on the sociodemographic factors. Special interventions should be conducted to raise drug treatment awareness among patients having insight and their caregivers.
format Online
Article
Text
id pubmed-9120996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91209962022-06-01 A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue Tripathi, Raakhi Jalgaonkar, Sharmila Gajbhiye, Snehalata Khatri, Nishtha Sayyed, Mohsin Parkar, Shubhangi Indian J Psychol Med Original Articles BACKGROUND: Schizophrenia is associated with high relapse rates, and medication nonadherence is a major factor contributing toward relapse. Since medication adherence and treatment awareness are linked, an alarming need was felt to evaluate the level of drug treatment awareness in patients who have schizophrenia. Besides, patients who have schizophrenia are often dependent on their caregivers for medications. Hence, the current study was also designed to look into drug treatment awareness among caregivers. METHODS: This was a cross-sectional, questionnaire-based study. Patients diagnosed with schizophrenia as per The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition were included, provided they had good insight and had been prescribed medications at the study center for at least three months. Caregivers were included using the Pollak and Perlick criteria. The sociodemographic profile of the patients and caregivers was recorded, and further assessment for treatment awareness was done using the prevalidated Drug Treatment Awareness Questionnaire (DTAQ). RESULTS: A total of 166 patients and 157 caregivers were enrolled. Mean drug awareness scores among patients and caregivers did not show statistically significant differences (P= 0.22). Mean ± SD DTAQ awareness scores in patients and caregivers were 12.57 ± 1.81 and 12.84 ± 1.91, respectively. The majority of patients and caregivers (> 90%) possessed awareness in domains related to past medication records and in that of re-visit/re-contact instructions. Awareness was least commonly seen in relation to side effects of medications and details of the prescribed medications, where only about 50% of patients and caregivers possessed awareness. No clinically significant correlation was found between sociodemographic factors and drug treatment awareness scores. CONCLUSION: Drug treatment awareness in patients and caregivers was comparable and was not reliant on the sociodemographic factors. Special interventions should be conducted to raise drug treatment awareness among patients having insight and their caregivers. SAGE Publications 2021-12-21 2022-03 /pmc/articles/PMC9120996/ /pubmed/35655976 http://dx.doi.org/10.1177/02537176211056358 Text en © 2021 Indian Psychiatric Society - South Zonal Branch https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Tripathi, Raakhi
Jalgaonkar, Sharmila
Gajbhiye, Snehalata
Khatri, Nishtha
Sayyed, Mohsin
Parkar, Shubhangi
A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue
title A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue
title_full A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue
title_fullStr A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue
title_full_unstemmed A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue
title_short A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue
title_sort cross-sectional, questionnaire-based study on drug treatment awareness in schizophrenia patients and caregivers: an unexplored avenue
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120996/
https://www.ncbi.nlm.nih.gov/pubmed/35655976
http://dx.doi.org/10.1177/02537176211056358
work_keys_str_mv AT tripathiraakhi acrosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT jalgaonkarsharmila acrosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT gajbhiyesnehalata acrosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT khatrinishtha acrosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT sayyedmohsin acrosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT parkarshubhangi acrosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT tripathiraakhi crosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT jalgaonkarsharmila crosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT gajbhiyesnehalata crosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT khatrinishtha crosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT sayyedmohsin crosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue
AT parkarshubhangi crosssectionalquestionnairebasedstudyondrugtreatmentawarenessinschizophreniapatientsandcaregiversanunexploredavenue